Background: Myricetin is a naturally occurring antioxidant commonly found in various plants. However, little information is available with respect to its direct anti-obesity effects. Objective: This study was undertaken to investigate the effect of myricetin on high-fat diet (HFD)-induced obesity in C57BL/6 mice. Results: Administration of myricetin dramatically reduced the body weight of diet-induced obese mice compared with solely HFD-induced mice. Several parameters related to obesity including serum glucose, triglyceride, and cholesterol were significantly decreased in myricetin-treated mice. Moreover, obesity-associated oxidative stress (glutathione peroxidase (GPX) activity, total antioxidant capacity (T-AOC), and malondialdehyde (MDA)) and inflammation (tumor necrosis factor-α (TNF-α)) were ameliorated in myricetin-treated mice. Further investigation revealed that the protective effect of myricetin against HFD-induced obesity in mice appeared to be partially mediated through the down-regulation of mRNA expression of adipogenic transcription factors peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancerbinding protein α (C/EBPα), and lipogenic transcription factor sterol regulatory element-binding protein 1c . Conclusions: Consumption of myricetin may help to prevent obesity and obesity-related metabolic complications.
Introduction
The World Health Organization (WHO) has estimated that globally more than 1.4 billion individuals are overweight or obese (Ng et al., 2014) . A growing body of evidence confirms that obesity is closely associated with a series of chronic diseases, such as type 2 diabetes mellitus, cardiovascular diseases, nonalcoholic fatty liver disease (NAFLD), dyslipidemia, and certain cancers (Grundy, 1998; Tilg and Moschen, 2006) . The high prevalence of obesity has made it a serious public health concern. Several factors including genetic, environmental, and psychological factors greatly influence the occurrence and development of obesity. Recently, increasing attention has been paid to exploiting natural components extracted from a normal diet as a viable strategy to inhibit the onset of obesity (Yun, 2010; Jeong et al., 2014) . Some blended phytochemicals from fruits and vegetables reportedly have the potential to suppress dietinduced obesity (Song et al., 2013; Zhao et al., 2015) .
Oxidative stress has been implicated in the development of obesity-related metabolic disorders, such as cardiovascular diseases, atherosclerosis, and hypertension (Furukawa et al., 2004; Galinier et al., 2006) . Antioxidant defense systems may be impaired as a consequence of excessive oxidative stress in obesity (Furukawa et al., 2004) . In addition, obesity is associated with a chronic, low-grade inflammatory state. Obesity-related inflammatory responses can be partially mediated by oxidative stress (Wood et al., 2009) . Targeted intervention of inflammatory pathways may help to prevent obesity-associated metabolic disorders (Gregor and Hotamisligil, 2011) . Naturally occurring antioxidant compounds including flavonoids, anthocyanidins, and catechins have been reported to affect the regulation of lipid metabolism through modulating oxidative stress conditions (Hogan et al., 2010; Yen et al., 2011) .
Myricetin is a major flavonoid found in various foods, including onions, bayberries, grapes, and tea (Harnly et al., 2006; Chen W. et al., 2011; Li et al., 2012) . Accumulating evidence shows that myricetin has antioxidant, anti-inflammatory, and anticancer activities (Lu et al., 2006; Chen et al., 2013a; . In addition, it can lower plasma-glucose levels, improve the insulin-signaling pathway, and reduce hyperglycemia (Ong and Khoo, 2000; Liu et al., 2005; . Myricetin is also confirmed to have therapeutic benefits in relation to cardiovascular diseases associated with obesity (Ong and Khoo, 1997) . However, little information is available with respect to the direct anti-obesity effects of myricetin on high-fat diet (HFD)-induced C57BL/6 mice through modulating the oxidative stress pathway.
In this study, we aimed to investigate the effects of myricetin on the development of obesity in HFDinduced C57BL/6 mice by examining serum glucose, triglyceride (TG), and cholesterol profiles as well as oxidative stress indicators. We then evaluated the gene expression of adipogenesis-and lipogenesisrelated transcription factors in epididymal white adipocytes. Our results provide a foundation for future studies on the application of myricetin for the preclinical prevention and treatment of obesity.
Materials and methods

Reagents
Myricetin (purity >96%) was obtained from the National Institutes for Food and Drug Control (Beijing, China). Oil Red O was purchased from SigmaAldrich Co. (CA, USA), TRIzol from Invitrogen (Carlsbad, CA, USA), and SYBR Green PCR Master Mix from Roche (Basel, Switzerland). All other reagents used were of analytical grade.
Animal experiments
All the animal experimental procedures in this study were conducted in the Animal Experiment Center of Zhejiang University (Hangzhou, China). The animal protocol was approved by the Institutional Animal Care and Use Committee of Zhejiang University. Animal diets were obtained from Medicience Ltd. (Yangzhou, China). Myricetin was dissolved in normal saline (NS)/Tween-80 (25:1, v/v) by grinding with a mortar and pestle. Male C57BL/6 mice at 4 weeks of age were purchased from the Silaike Experimental Animal Co., Ltd. (Shanghai, China). The mice were housed in a pathogen-free facility under a 12-h light/12-h dark cycle ((22±2) °C, 40%-70% relative humidity), and had ad libitum access to water and diet. After 5-d adaptation, the mice were randomly divided into two groups: a normal diet group (ND) fed a diet containing 10% fat, and an HFD group fed a diet containing 45% fat. Both diets were maintained for 2 weeks. For the obesity challenge study: (1) 12 mice in the ND group were fed an ND administered with vehicle (NS/Tween-80 (25:1, v/v)) by oral gavage; (2) 12 mice in the HFD group were fed an HFD administered with vehicle (NS/Tween-80 (25:1, v/v)) by oral gavage; (3) another 12 mice in the HFD group were fed an HFD with myricetin at 150 mg/(kg·d) (M150), in accordance with Choi et al. (2014) . All mice were permitted ad libitum consumption of water. After 10 weeks, all mice were sacrificed following 12-h fasting. Blood samples were collected, and liver and adipose tissue samples were collected, weighed, and stored at −80 °C for further assessment.
Biochemical analyses
The blood samples were centrifuged at 3000 r/min for 15 min and then were collected for biochemical analyses. Serum glucose, TG, total cholesterol (TC), and malondialdehyde (MDA) levels were measured using commercial enzyme kits (Elabscience, China) according to the manufacturer's protocols. Glutathione peroxidase (GPX), superoxide dismutase (SOD), and total antioxidant capacity (T-AOC) were determined by enzymatic methods using ELISA kits (Sigma, CA, USA) according to the manufacturer's instructions (Wu et al., 2013c; Yu et al., 2016) .
Hematoxylin and eosin staining
Morphological analysis of adipocytes was performed on hematoxylin and eosin (H&E)-stained sections as described (Wu et al., 2013a) . Epididymal white adipose tissue samples were dissected and fixed in 10% formalin for 24 h, then dehydrated by ethanol solutions. The samples were then embedded in paraffin wax and sliced. The fixed tissue slices were stained with H&E, mounted by neutral sizing, and dried. Images were obtained using a Nikon microscope (Tokyo, Japan).
Oil Red O staining
Oil Red O staining was performed as described by Wu et al. (2013b) . Sections, approximately 4-5 µm thick, were cut from liver tissue using a freeze microtome. The sections were fixed in 4% formaldehyde for 20 min and then stained with Oil Red O for 30 min. The slices were washed with 60% isopropanol three times to remove unbound dye and were then photographed. Images were obtained using a Nikon microscope.
Real-time reverse transcription-PCR
Real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis was performed as described by Wu et al. (2014) and Lei et al. (2015) . Total RNA was isolated from the epididymal adipose tissue of each mouse using TRIzol (Invitrogen) and then pooled for the RT-PCR analysis. Single-stranded complementary DNA (cDNA) was synthesized using the PrimeScript RT reagent kit (TaKaRa, Japan) according to the manufacturer's instruction. Quantitative real-time PCR was carried out using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The 20-μl reaction mixture consisted of 1× SYBR Green PCR Master Mix, 0.25 μmol/L of cDNA, and 0.2 μmol/L of each primer. The PCR conditions were as follows: denaturation for 10 min at 95 °C, followed by 40 cycles at 95 °C for 10 s, and then at 60 °C for 60 s. The following primers were used: PPARγ, 5'-CGC TGA TGC ACT GCC TAT GA-3' (forward) and 5'-AGA GGT CCA CAG AGC TGA TTC-3' (reverse); C/EBP-α, 5'-AGC AAC GAG TAC CGG GTA CG-3' (forward) and 5'-TGT TTG GCT TTA TCT CGG CTC-3' (reverse); SREBP-1c, 5'-TTG TGG AGC TCA AAG ACC TG-3' (forward) and 5'-TGC AAG AAG CGG ATG TAG TC-3' (reverse); β-ACTIN, 5'-ATG TGG ATC AGC AAG CAG GA-3' (forward) and 5'-AAG GGT GTA AAA CGC AGC TCA-3' (reverse). A relative gene-expression quantification method was used to calculate the fold change in mRNA expression according to the comparative C T method using β-ACTIN for normalization. Results were obtained from at least three independent experiments.
Statistical analysis
All experimental data were analyzed using SPSS (Version 20.0) and expressed as the mean±standard deviation (SD). One-way analysis of variance (ANOVA) was used to evaluate the statistical differences among different groups. A P-value of <0.05 was considered statistically significant.
Results
Myricetin ameliorates obesity in HFD-induced mice
In the current study, C57BL/6 mice were fed an ND, HFD, or HFD+M (150 mg/(kg·d)) by oral gavage for 10 weeks. HFD-fed mice had a significantly higher body weight than ND-fed mice (Fig. 1a) . Administration of myricetin significantly reduced the body weight of mice fed an HFD. At the end of the experiments, a 19.8% reduction in body weight was observed in the myricetin-treated group relative to the HFD-fed control group. There were no significant differences in the food or calorie intake between the HFD and HFD+M groups (Figs. 1b and 1c) , suggesting that food intake did not have a significant role in the manipulation of the body weight of the mice.
Myricetin reduces visceral fat in HFD-induced mice
To determine the effect of myricetin on visceral fat, mice adipose tissues were excised and weighed. The HFD led to significant increases in epididymal (148.2%, Fig. 1d ), subcutaneous (208.7%, Fig. 1e) , perirenal (205.6%, Fig. 1f ), and total (170.4%, Fig. 1g ) fat relative to the ND-fed group. Consistent with our expectation, administration of myricetin significantly reduced these increases, to 43.2% (epididymal), 46.5% (subcutaneous), 49.1% (perirenal), and 45.3% (total fat). In conclusion, myricetin provides protection against obesity in HFD-induced mice by decreasing visceral fat accumulation.
Myricetin reduces serum biochemical parameters in HFD-induced mice
Obesity is accepted as a chronic disease which is associated with alteration of serum parameters. Therefore, we investigated serum glucose (Fig. 2a) , total TG (Fig. 2b) , and cholesterol (Fig. 2c ) concentrations with or without myricetin treatment. The glucose and total TG levels were significantly elevated in the HFD treatment group. However, there were no significant differences in the levels of glucose and TG between the ND group and the myricetin-treated group. Myricetin-treated mice also showed a slight reduction in serum cholesterol compared with those in the HFD-induced group.
Effects of myricetin on adiponectin, leptin, TNF-α, and insulin
We determined adiponectin, leptin, tumor necrosis factor-α (TNF-α), and insulin levels. The HFD group showed a 28.17% reduction in serum adiponectin compared with the ND group (Fig. 3a) . Administration of myricetin resulted in a 15.77% increase in adiponectin compared with the HFD-treated group. The leptin level was significantly increased by 100% in HFD-fed mice relative to ND-fed mice. However, in mice receiving myricetin the increase in leptin level was reduced to 55.34% (Fig. 3b) . Next, we investigated the effect of myricetin administration on the inflammation marker TNF-α in HFD-induced mice. A marked increase in the production of TNF-α was observed in HFD-fed mice compared with NDfed mice (Fig. 3c) . The myricetin treatment group showed a much smaller increase in TNF-α content. To identify the effect of myricetin on obesity-associated insulin resistance, we determined the insulin level. The HFD significantly increased the insulin level by 28.63%, whereas myricetin-treated mice had slightly less insulin than those in the ND group (Fig. 3d) .
Effects of myricetin on serum antioxidant capacity
A growing amount of evidence indicates that obesity is linked to excessive oxidative stress. Therefore, we investigated the antioxidant capacity of myricetin in HFD-fed mice. GPX is an important endogenous antioxidant enzyme that is responsible for reactive oxygen species (ROS) scavenging. The serum GPX content was 24.6% lower in the HFD group than in the ND group (Fig. 4a) . Administration of myricetin significantly elevated the amount of GPX by 49.6% compared with the amount in the HFD group. Our results showed a significant elevation of MDA level by 51.7% in the HFD group compared with that in the ND-treated group (Fig. 4b ). However, the MDA level in the myricetin-treated group showed no significant increase, suggesting that myricetin could correct the lipid peroxidation condition. Further investigation showed that there were no significant differences in serum SOD activity among ND, HFD, and myricetin-treated groups (Fig. 4c) . In addition, myricetin showed the ability to overcome the reduction in T-AOC induced by the HFD (Fig. 4d) . 
Effects of myricetin on morphology of white adipose and liver tissues
To characterize the morphological change in adipocytes at the end of myricetin treatment, we analyzed the epididymal white adipose tissue samples. The adipocytes in the ND group were small with clear morphology and complete structure (Fig. 5a) . Adipocytes of the HFD group showed an uneven size and irregular arrangement. Strikingly, a decrease in the diameter of adipocytes of epididymal fats was noticed in mice treated with myricetin compared with those in the HFD group. Based on these observations, we conclude that myricetin can suppress fat accumulation in white adipose tissue. Next, we performed a histological analysis of liver sections from mice receiving diets with or without myricetin (Fig. 5b) . The liver sections were stained by Oil Red O and then examined by microscopic imaging. The liver sections from HFD-fed mice exhibited a red color indicative of lipid accumulation. Conversely, administration of myricetin attenuated HFD-induced fat accumulation in the liver tissue.
Effects of myricetin on obesity-related transcription factors in epididymal white adipose tissue
The reduction in body weight of HFD-induced mice receiving myricetin suggested that myricetin was capable of regulating transcription factors involved in adipogenesis (including adipogenic genes: peroxisome proliferator-activated receptor γ (PPARγ), CCAAT/enhancer-binding protein α (C/EBPα)) and lipogenesis (sterol regulatory element-binding protein 1c (SREBP-1c) ). The fold change in gene expression in epididymal white adipocytes was measured by (Figs. 6a and 6b) . Administration of myricetin significantly reduced HFD-induced upregulation of PPARγ and C/EBPα. SREBP-1c was also markedly higher in HFD-fed mice than in ND-fed mice (Fig. 6c) . Mice receiving myricetin showed reduced SREBP-1c gene expression compared with HFD-fed mice. In conclusion, our results suggest that myricetin appeared to inhibit obesity partly by down-regulation of adipogenesisand lipogenesis-related gene expressions.
Discussion
The prevalence and severity of obesity are growing worldwide (Ng et al., 2014) . Several Food and Drug Administration (FDA)-approved anti-obesity drugs are commercially available for use in weight control and weight reduction, but undesirable sideeffects have made it difficult for obese patients to achieve long-term maintenance of weight loss (ColonGonzalez et al., 2012; Wong et al., 2012) . Therefore, safer and efficacious agents are needed urgently to inhibit the occurrence and development of obesity on a long-term basis. Recently, several natural phytochemicals derived from fruits and vegetables have been demonstrated to suppress obesity and obesityrelated metabolic syndrome (Keophiphath et al., 2009; Chen Y.K. et al., 2011; Ueda and Ashida, 2012) . In the present study, we found that myricetin, a naturally occurring small molecule, could provide protection against HFD-induced obesity in C57BL/6 mice.
HFD leads to a progressive gain in body weight both in humans and animals. In this study, HFD caused elevated body weight in C57BL/6 mice, but administration of myricetin attenuated the HFDinduced weight gain. Given that there were no significant differences in food and calorie intake between the HFD and HFD+M groups, we conclude that the appetites of the mice were unaffected by myricetin treatment. Myricetin administration also attenuated increases in glucose, total TG, and TC levels in the serum caused by HFD. Leptin is an adipocyte-derived hormone that contributes to maintenance of food intake and improvement of energy homeostasis in peripheral tissues, such as the liver and muscle (Kim and Park, 2011) . After HFD treatment, leptin levels increased notably in our experiment, in accordance with a previous report (Frederich et al., 1995) . Adiponectin, produced by adipose tissue, has been shown to stimulate food intake and decrease energy expenditure (Kubota et al., 2007) . We found that administration of myricetin increased the levels of leptin and decreased the levels of adiponectin in obese mice, suggesting that adiponectin and leptin are involved in the antiobesity action of myricetin.
Excessive oxidative stress has been characterized in obesity and obesity-related metabolic complications. Accumulating evidence suggests that antioxidant defense systems are impaired in dietinduced obesity (Hogan et al., 2010; Yen et al., 2011) . GPXs play a pivotal role in the maintenance of physiologically produced ROS. MDA, as an important lipid peroxidation product, has been used as a marker for evaluation of oxidative stress. In the present study, we found myricetin significantly promoted GPX activity and decreased MDA levels in HFD-fed mice, suggesting that myricetin could improve antioxidant capacity in vivo. Oxidative stress is closely linked to inflammation in obesity (Wood et al., 2009 ) and elevated pro-inflammatory cytokines have been reported to augment the development of the metabolic syndrome associated with obesity (Hotamisligil et al., 1996) . TNF-α is a pro-inflammatory cytokine that has a critical role in multiple inflammatory diseases, including obesity, diabetes, osteoporosis, and rheumatoid arthritis (Feldmann and Maini, 2001; Xu et al., 2002; Tweedie et al., 2007) . We found that administration of myricetin reduced TNF-α levels in HFD-induced mice. Collectively, these results suggest that the development of obesity and obesityrelated metabolic syndrome could be prevented by myricetin through modulating oxidative stress conditions.
Adipose tissue grows by hypertrophy (cell size increase) and hyperplasia (cell number increase) in obese mice. Lipid is stored in adipose tissues when energy intake exceeds energy expenditure, resulting in hypertrophy and body weight gain (Kim and Park, 2011) . Myricetin treatment effectively reduced the size and number of epididymal adipocytes and hepatocytes, and lessened fat mass compared with the HFD-induced mice without myricetin. This observation suggests that myricetin might inhibit the process of adipogenesis and lipid accumulation during cell differentiation. To gain more mechanistic insight into the anti-obesity effect of myricetin, we examined the expression of lipogenic-and adipogenic-related genes. PPARγ and C/EBPα are regulators of many genes involved in the adipose phenotype and lipid metabolism (Hou et al., 2012) . Administration of myricetin resulted in a down-regulation of PPARγ and C/EBPα. SREBP-1c regulates the expression of target genes involved in fatty acid synthesis (Joseph et al., 2002) . The pronounced decrease in serum and hepatic TG found in the myricetin-treated group suggests that altered gene expression of SREBP-1c in adipocytes might be an underlying mechanism. This hypothesis was confirmed by the observation that the expression of lipogenic transcription factor SREBP-1c was suppressed by myricetin treatment. Taken together, these observations suggest that myricetin may suppress the expression of adipogenic and lipogenic genes, thereby regulating the onset of obesity.
Conclusions
In summary, the present study showed that myricetin decreased serum glucose levels, regulated lipid metabolism, and provided protection against HFDinduced oxidative stress in obese mice. A further mechanistic study revealed that administration of myricetin down-regulated the expression of adipogenic (PPARγ and C/EBPα) and lipogenic (SREBP-1c) genes in HFD-induced mice. No deaths or abnormalities resulted from this experiment. Therefore, myricetin may be a safe and effective agent for preventing obesity. However, there is no direct evidence showing that myricetin has the same anti-obesity capability in humans and therefore future clinical studies need to be considered.
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